Expectations are falling for a key drug in its pipeline.
Shares in the company are slipping as short-sellers call into question one of its most important clinical-stage drugs.
Good news for a rival drug translates to bad news for Tesaro.
Investors are growing more bullish on the shipping stock.
A marijuana-focused sell-off weighs on the company. Here's what you should know.
A big loss despite a lack of news for the precommercial biotech.
Customers can't get enough of PetMeds' convenience.
The biotech's drug works -- just not on as many people as investors would have hoped for.
The biopharma stock fell on excellent news -- for the competition.
The CEO doesn't want to sell -- but will he have a choice?
It's a sellout -- of the best kind.
Shares tumbled after the company reported clinical data from an important phase 2 trial. Here's what investors need to know.
Shares of the department-store operator have still shown life even after bankruptcy. Here's why.
The Dutch lighting and medical imaging giant fell short of analyst expectations in the third quarter but still held firm to its full-year goals.
Data presented at a medical conference weren't as good as investors were hoping for.
Encouraging clinical data helps the beaten-down biotech to recover.
The advertising leader delivered solid quarterly results and reiterated its full-year guidance.
Some investors booked profits following the company's recent cystic fibrosis trial data.
The company's shares are lower today as investors take a breather from a month filled with speculation and rumors.
One bearish analyst pointed out some glaring flaws in AMD's share price and performance expectations.